John O’Bryan

John O’Bryan

Company: Medical University of South Carolina

Job title: Professor - Cell, Molecular Pharmacology & Experimental Therapeutics


Current Progress in Defining New Vulnerabilities in RAS That Can Be Exploited to Therapeutically Inhibit KRAS-Mutant Cancers 1:00 pm

A new approach to inhibit the oncogenic KRAS by selectively targeting the nucleotide-free (apo) state of the protein Isolation of a monobody termed R15 that selectively binds apo RAS in vitro. When expressed in cells, R15 binds and inhibits oncogenic KRAS mutants with elevated spontaneous nucleotide release rates Contrary to conventional wisdom, it is possible…Read more

day: Day Two Track B

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.